Premium
Defining the HLA class I‐associated viral antigen repertoire from HIV‐1‐infected human cells
Author(s) -
Ternette Nicola,
Yang Hongbing,
Partridge Thomas,
Llano Anuska,
Cedeño Samandhy,
Fischer Roman,
Charles Philip D.,
Dudek Nadine L.,
Mothe Beatriz,
Crespo Manuel,
Fischer William M.,
Korber Bette T. M.,
Nielsen Morten,
Borrow Persephone,
Purcell Anthony W.,
Brander Christian,
Dorrell Lucy,
Kessler Benedikt M.,
Hanke Tomáš
Publication year - 2016
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.201545890
Subject(s) - human leukocyte antigen , biology , cytotoxic t cell , antigen presentation , virology , epitope , antigen , immunology , antigen processing , t cell , computational biology , immune system , genetics , in vitro
Recognition and eradication of infected cells by cytotoxic T lymphocytes is a key defense mechanism against intracellular pathogens. High‐throughput definition of HLA class I‐associated immunopeptidomes by mass spectrometry is an increasingly important analytical tool to advance our understanding of the induction of T‐cell responses against pathogens such as HIV‐1. We utilized a liquid chromatography tandem mass spectrometry workflow including de novo‐assisted database searching to define the HLA class I‐associated immunopeptidome of HIV‐1‐infected human cells. We here report for the first time the identification of 75 HIV‐1‐derived peptides bound to HLA class I complexes that were purified directly from HIV‐1‐infected human primary CD4 + T cells and the C8166 human T‐cell line. Importantly, one‐third of eluted HIV‐1 peptides had not been previously known to be presented by HLA class I. Over 82% of the identified sequences originated from viral protein regions for which T‐cell responses have previously been reported but for which the precise HLA class I‐binding sequences have not yet been defined. These results validate and expand the current knowledge of virus‐specific antigenic peptide presentation during HIV‐1 infection and provide novel targets for T‐cell vaccine development.